injectable tirzepatide in Mountain View, WY led and built for women Tirzepatide Flex-Dose 1 mL Injectable

Neelam, Khatkar A, Sharma KK

Combining these approaches often yields optimal results

E N D Presentation Transcript GLP-1 Agonists and Cardiovascular Health Alan Mathis PharmD Candidate 2013 www.DIABETESINCONTROL.COM Part 2 of 2 Change in Triglycerides and HDL-C as Function of Weight-Change Quartile at 82 Weeks Effects of GLP-1 agonists on inflammatory markers GLP-1 agonists have been shown to reduce several inflammatory markers including plasminogen activator inhibitor-1 (PAI-1), vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1) E-selectin was not significantly reduced C-reactive protein has also been associated with increased cardiovascular disease Patients treated with exenatide showed marked decrease in c-reactive protein levels after an 82-week study (from 3.21mg/dL to 1.35 mg/dL) Kendall DM, Bhole D, Guan X, et al.: Exenatide treatment for 82 weeks reduced C-reactive protein, HbAlc, and body weight in patients with type 2 diabetes mellitus

From the enquiries we have been getting for tirzepatide, we reckon that it is going to be one big hit drug in many markets across the world, said Singha

My labs have never looked better and my energy is steady all day